Atomo Diagnostics Ltd (ASX:AT1)
A$ 0.02 0 (0%) Market Cap: 12.78 Mil Enterprise Value: 9.24 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 0/100

Q4 2023 Atomo Diagnostics Ltd Activities Report Call Transcript

Jul 26, 2023 / 11:30PM GMT
Release Date Price: A$0.03 (-6.25%)
John Michael Kelly
Atomo Diagnostics Limited - Founder, CEO, MD & Director

Hello. Thank you, and welcome, everyone, for the Atomo quarterly activity report. Myself, John Kelly and Will Souter our CFO, are presenting today. We're in different locations because I'm in the U.S. attending AACC, which is the large U.S. Clinical Chemistry and Diagnostics Conference, and we'll talk a little bit about what we're doing here and the kind of progress we've been making in -- later in the presentation.

First, just to run into the quarterly highlights themselves. We'll start with our main product HIV Self Test. We're seeing significant interest in the product across a range of different territories and categories continued sales in global health and expectations are on some larger tenders coming out of that process as HIV screening gets back on track, both COVID and global health.

We're seeing some significant opportunities emerge in the Australian market quarter-on-quarter growth in the first half of this calendar year. We're expecting to see that continue as we roll into more pharmacies, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot